Parabolic Drugs Limited reported unaudited earnings results for the second quarter and half year ended September 30, 2018. For the quarter, the company reported net sales (net of excise duty) of INR 49.2 million compared to INR 239.6 million a year ago. Loss before extraordinary items and tax was INR 136.3 million compared to INR 137.8 million a year ago. Net loss after tax from continuing operations was INR 143.5 million or INR 2.32 per basic and diluted share compared to INR 142.3 million or INR 2.30 per basic and diluted share a year ago. For the half year, the company reported net sales (net of excise duty) of INR 177.7 million compared to INR 392.9 million a year ago. Loss before extraordinary items and tax was INR 253.6 million compared to INR 259.4 million a year ago. Net loss after tax from continuing operations was INR 248.8 million or INR 4.02 per basic and diluted share compared to INR 268.4 million or INR 4.34 per basic and diluted share a year ago.